Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy Anthera Pharmaceuticals Inc (ANTH) Following Public Offering Of Common Shares?

In an effort to generate funds for clinical research and development and other general corporate purposes, Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced earlier today that it is planning to sell shares of common stock in an underwritten public offering. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) is planning to offer these shares at $7.50 per share, and is expecting to generate around $25 million from the proceeds, before deducting discounts, commissions and other expenses related to the offering. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) stock is soaring this year to say the least, as it has gained more than 385% year-to-date (yes, that is not a typo), even factoring in today’s drop of around 8% following the announcement of the underwritten public offering. The offering is a necessary move, as the company lost $7.7 million in the first quarter through its operations. It currently has no products on the market, with the biotech firm’s lead candidate being the lupus treatment blisibimod.


Looking at the hedge fund activity on Anthera Pharmaceuticals Inc (NASDAQ:ANTH), we can see there is optimism for the company’s product candidates, as there were nine hedge funds with $26.1 million in shares of the company at the end of March, up from seven hedge funds with $9.1 million in holdings in the stock at the end of 2014. However, given that the stock jumped by 183% and hedge funds’ resulting holdings were up by 186%, we can see that there wasn’t much of an increase in overall share ownership, even as two more funds bought into the stock.

Most investors don’t understand hedge funds and indicators that are based on hedge fund and insider activity. They ignore hedge funds because of their recent poor performance in the long-running bull market. Our research indicates that hedge funds underperformed because they aren’t 100% long. Hedge fund fees are also very large compared to the returns generated and they reduce the net returns enjoyed (or not) by investors. We uncovered through extensive research that hedge funds’ long positions in small-cap stocks actually greatly outperformed the market from 1999 to 2012, and built a system around this. The 15 most popular small-cap stocks among funds beat the S&P 500 Index by more than 80 percentage points since the end of August 2012 when this system went live, returning a cumulative 135% vs. less than 55% for the S&P 500 Index (read the details).

Likewise, other research (not our own) has shown insider purchases are also effective piggybacking methods for investors. That’s why we believe investors should pay attention to what hedge funds and insiders are buying and keep them apprised of this information. However there was no insider activity in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) during the first half of 2015.

Keeping this in mind, let’s take a look at the latest hedge fund activity regarding Anthera Pharmaceuticals Inc (NASDAQ:ANTH).

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.